Coronbot Bio (06990.HK): The core product TROP2ADC sacituzumab govitecan (sac-TMT) combined with pembrolizumab achieved the primary endpoint in a Phase 3 clinical study for first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer with PD-L1 negativity.

Smart Finance APP News, Collen Biolab (06990.HK) announced that the company's antibody-drug conjugate (ADC) targeting the surface antigen 2 of human nourishing cells (TROP2) - sacituzumab govitecan (sac-TMT, also known as SKB264/MK-2870) (Jiatle) in combination with Merck's anti-programmed cell death protein-1 (PD-1) monoclonal antibody (mAb) pembrolizumab (Keytruda) has achieved the primary endpoint of progression-free survival (PFS) in the phase 3 clinical study OptiTROP-Lung06 for first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that is negative for programmed cell death ligand-1 (PD-L1) in the pre-specified interim analysis, confirmed by an independent data monitoring committee (IDMC). This is the world's first phase 3 clinical study where an ADC in combination with immune checkpoint inhibitors has achieved the primary endpoint in first-line treatment of driver gene-negative, PD-L1-negative non-squamous NSCLC.